S&P ASX All Technology

US Dollar vs AUD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

SGMO Sangamo Therapeutics Inc

0.5323

-0.0115 (-2.11%)

After Hours

Last Updated: 09:00:01

Delayed by 15 minutes

Confidential Treatment Order (ct Order)

This regulatory filing also includes additional resources:
filename1.pdf

Sangamo Therapeutics (NASDAQ:SGMO)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Sangamo Therapeutics Charts.

Sangamo Therapeutics (NASDAQ:SGMO)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Sangamo Therapeutics Charts.

Sangamo Therapeutics, Inc News

Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
Friday 3 May 2024 (3 hours ago) • Business Wire

Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Tuesday 23 April 2024 (1 week ago) • Business Wire

Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
Friday 22 March 2024 (1 month ago) • Business Wire

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
Wednesday 13 March 2024 (2 months ago) • Business Wire

Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
Wednesday 13 March 2024 (2 months ago) • Business Wire

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
Wednesday 13 March 2024 (2 months ago) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 28 February 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 28 February 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 28 February 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 28 February 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 28 February 2024 (2 months ago) • Edgar (US Regulatory)

Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease
Tuesday 13 February 2024 (3 months ago) • Business Wire

More Sangamo Therapeutics, Inc News Articles

AUD vs US Dollar

Verizon Communications

Australia And New Zealan...

Invesco QQQ Trust Series 1

Australian SE All Ordina...

Sterling vs AUD

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions